Author:
Borrie Adrienne E.,Maleki Vareki Saman
Reference262 articles.
1. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy;Agrawal;J. Immunother Cancer,2016
2. Model-based characterization of the pharmacokinetics of pembrolizumab: a humanized anti-PD-1 monoclonal antibody in advanced solid tumors;Ahamadi;CPT Pharmacometrics Syst. Pharmacol.,2017
3. Characterization of human inducible costimulator ligand expression and function;Aicher;J. Immunol.,2000
4. INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors;Angevin;J. Clin. Oncol.,2017
5. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study;Antonia;Lancet Oncol.,2016
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献